Adalimumab Effective in Children and Adolescents With Severe Psoriasis Adalimumab Effective in Children and Adolescents With Severe Psoriasis
Adalimumab offers benefits over methotrexate in children and adolescents with severe chronic plaque psoriasis, according to a phase 3 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2017 Category: Consumer Health News Tags: Pediatrics News Source Type: news
Mayo Clinic Q and A: Treatment often can keep morphea symptoms in check
DEAR MAYO CLINIC: About six months ago, a large, white dent appeared on my left buttock. After a biopsy, I was diagnosed with morphea. I was told that it is not systemic, but that the drug methotrexate could prevent future skin lesions and possibly cure the morphea. Is this possible, and what are the risks [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 6, 2017 Category: Databases & Libraries Source Type: news
Xatmep (Methotrexate Oral Solution) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 4, 2017 Category: Drugs & Pharmacology Source Type: news
Baricitinib for RA Bests Methotrexate at 1 Year (CME/CE)
(MedPage Today) -- Daily oral JAK inhibitor improves most disease measures (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 28, 2017 Category: Geriatrics Source Type: news
BSR: Baricitinib for RA Bests Methotrexate at 1 Year (CME/CE)
(MedPage Today) -- Daily oral JAK inhibitor improves most disease measures (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 28, 2017 Category: Geriatrics Source Type: news
BSR: Genetic Analysis IDs Methotrexate Responders (CME/CE)
(MedPage Today) -- Gene biomarkers differentiated between good responders and nonresponders (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 28, 2017 Category: Geriatrics Source Type: news
FDA Approves Xatmep (methotrexate) Oral Solution
Denver, April 26, 2017 — Silvergate Pharmaceuticals, Inc. leaders in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved Xatmep... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 26, 2017 Category: Drugs & Pharmacology Source Type: news
FDA Approves XATMEP(TM), the First and Only Ready-To-Use Methotrexate Oral Solution
DENVER, April 26, 2017 -- (Healthcare Sales & Marketing Network) -- Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leaders in the development and commercialization of innovative and safe medicines for children, today announced that the Unite... Biopharmaceuticals, FDA Silvergate Pharmaceuticals, XATMEP, methotrexate, arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 26, 2017 Category: Pharmaceuticals Source Type: news
Methotrexate Sodium Injection (New - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - April 24, 2017 Category: Drugs & Pharmacology Source Type: news
Rheumatoid arthritis patients 'have experienced progress in recent decades'
This study confirms how important early diagnosis and the commencement of treatment is. It is also encouraging to hear about the progress that has been made over the last 20 years. "Now the scientific community must continue to build on this, so that together we can continue to harness the power of exceptional science and make everyday life better for all people with arthritis." (Source: Arthritis Research UK)
Source: Arthritis Research UK - April 18, 2017 Category: Rheumatology Source Type: news
What Causes Uveitis?
Discussion
Inflammation of the middle layer of the eye, or uvea, is termed uveitis. Uveitis can be divided into anterior, intermediate or posterior uveitis by involving the anterior (iris and ciliary body), intermediate (vitreous) or posterior (choroid and usually retina) compartments. Panuveitis involves all 3 compartments. Duration can also be used to classify uveitis. Acute is 6 weeks and > 3 months is chronic persistent uveitis. Episodic periods of inactivity and reactivity that last more than 3 months are called recurrent uveitis. A third way to characterize uveitis is if it is granulomatous or not. Uveitis increas...
Source: PediatricEducation.org - April 3, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Moderate drinking 'does not risk liver damage for methotrexate users'
People receiving the common rheumatoidarthritis therapymethotrexate can safely drink moderate amounts of alcohol without running the risk of liver damage. This is according to a new study from the University of Manchester, funded by Arthritis Research UK, which shows that drinking 14 units of alcohol or fewer per week is not likely to cause any liver health issues. Sticking to modest levels of drinking'likely to be safe' Methotrexate is often taken over extended periods of time to limit or prevent joint damage and disability associated withrheumatoid arthritis. Generally, those receiving the drug are advised to abs...
Source: Arthritis Research UK - March 28, 2017 Category: Rheumatology Source Type: news
XELJANZ ® (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of moderate to severe active rheumatoid arthritis
Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). (Source: World Pharma News)
Source: World Pharma News - March 27, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
